Twitter | Search | |
This is the legacy version of twitter.com. We will be shutting it down on 15 December 2020. Please switch to a supported browser or device. You can see a list of supported browsers in our Help Center.
Kristin Higgins
Radiation Oncologist
262
Tweets
607
Following
992
Followers
Tweets
Kristin Higgins Nov 30
Excited for this tonight! If you are a patient with lung cancer or a caregiver, please join us!
Reply Retweet Like
Kristin Higgins Oct 28
Intriguing presentation from Dr. Kong - radiation sensitivity genotypic signature validated in RTOG 0617 pts. Wonderful discussion from . Love this work that moves forward individualized radiation dose decisions.
Reply Retweet Like
Kristin Higgins Oct 27
Check out this trial in progress poster on . NRG LU-006: A phase III randomized trial of pleurectomy/decortication + chemo +/- adjuvant hemithoracic IMRT.
Reply Retweet Like
Kristin Higgins Oct 25
There’s a lot of great content in the GU space this year ⁦⁦
Reply Retweet Like
Kristin Higgins Oct 24
Dose-intensified IMRT does not impact survival in GBM but proton arm is still accruing in NRG-BN001. Great presentation
Reply Retweet Like
Kristin Higgins retweeted
ASTRO Oct 21
. hosts Jamie Chaft, MD and at for a virtual discussion on treatment strategies for patients using with a focus on . Join us Sun 10/25 at 5PM ET for this ISS event
Reply Retweet Like
Kristin Higgins Oct 21
We’ve reached 28% of our planned accrual — Please think of this trial for your limited stage small cell patients!
Reply Retweet Like
Kristin Higgins retweeted
Jill Feldman Oct 16
TODAY! North America Conference on Lung Cancer starts today. Watch oral presentations, gain insight from panel discussions, network with peers & visit the exhibit hall.
Reply Retweet Like
Kristin Higgins Oct 5
Don't miss the Virtual Atlanta Lung Cancer Symposium on November 7th! We have wonderful speakers and a great multi-disciplinary program.
Reply Retweet Like
Kristin Higgins Oct 5
Congrats Terry 🎉🎉🎉!! Terry is wonderful and will be amazing in this role.
Reply Retweet Like
Kristin Higgins retweeted
IASLC Sep 24
The program is innovative and inclusive. Presentations will encompass all thoracic oncology specialties and will incorporate brief educational presentations by members of the Control and Smoking Cessation Committee.
Reply Retweet Like
Kristin Higgins Sep 20
Hats off to the investigators for completing this trial — not an easy feat. The data are clear that PORT does not benefit our patients and cardiopulmonary toxicities from mediastinal RT are not trivial.
Reply Retweet Like
Kristin Higgins Sep 19
Great to see PACIFIC update with median survival of 47.5 months for durva arm. Real progress for stage III NSCLC!
Reply Retweet Like
Kristin Higgins retweeted
Corinne Faivre-Finn Sep 19
indeed No change to SOC in LS-SCLC as established in the CONVERT study (BD RT 45 Gy+concurrent chemo)-studies are ongoing with IO such as LU005 watch this space!
Reply Retweet Like
Kristin Higgins Sep 14
Congrats Amy!! A well deserved accomplishment!
Reply Retweet Like
Kristin Higgins Sep 8
Such an inspiring story! A great read for anyone going through a lung cancer diagnosis.
Reply Retweet Like
Kristin Higgins retweeted
Emory Rad Onc Residents Sep 3
The future is now: molecular imaging based radiotherapy plans. Looking forward to Ashesh Jani talk about post-prostatectomy PET guided planning
Reply Retweet Like
Kristin Higgins retweeted
NRG Oncology Aug 30
The NRG-LU007 was recently activated. This study will test the addition of RT to the usual immune therapy treatment (atezolizumab) for patients with extensive stage small cell lung cancer ES-SCLC. Documents are posted on .
Reply Retweet Like
Kristin Higgins retweeted
IASLC Aug 17
Physical distancing will not stop the advancement of lung cancer research. Present your research while it is still fresh and highly relevant. Submit your abstract for and present it through virtual sessions. Submit by August 28, 2020:
Reply Retweet Like
Kristin Higgins retweeted
Cancer Trials Support Unit Aug 17
NRG-LU007 () RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: was activated on 8/17/20. To learn more, visit the protocol page on the CTSU members’ website or visit .
Reply Retweet Like